Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SCT650C in Healthy Volunteers
NCT05894707Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCT650C in psoriasis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 1 more (4 cohorts), sponsored by Sinocelltech Group Limited. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 weeks. Status: unknown.
02
Drugs
SCT650C
03
Conditions
psoriasisrheumatoid arthritis (RA)systemic lupus erythematosus (SLE)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05894707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894707.